ClinicalTrials.gg
Active, not recruitingNCT07723950Updated Oct 20, 2026

A Retrospective Database Study for the Development and Validation of Algorithms for Intracerebral Hemorrhage and Seizures in Alzheimer's Disease

An observational study in Alzheimer's Disease, sponsored by Eisai Inc.. Active, not recruiting at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-10-20.

Sponsored by Eisai Inc. · Observational

How we know

Updated Oct 20, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Retrospective
Enrollment
600
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Alzheimer Disease by Eisai Co., Ltd. — 7 open to participants now, 12 under way, 2 of them phase 3. Alzheimer Disease · Eisai Co., Ltd..

Planned enrollment
10th of 15
600 · median 2,000
Started
2026
with 4 others
Observational
15 of 46
6 open now
Primary completion
2029-12
later than 7 of 11 live
Registered
41st of 46
by date

Among the 46 studies in Alzheimer Disease by Eisai Co., Ltd., this one is the 10th largest by planned enrollment of the 15 observational ones that give a count, is one of 5 that started in 2026, is one of 15 observational ones, reaches primary completion later than 7 of the 11 other live ones, and was the 41st registered.

Alzheimer Disease

3,972 studies on the registry are indexed under Alzheimer Disease; 930 are open to participants now.

Browse Alzheimer Disease studies →

Open to participants now

7 of the 46 studies in Alzheimer Disease by Eisai Co., Ltd. are open now, in 4 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 645 Alzheimer Disease studies recruiting now, 282 (44%) set no upper age limit and 57 (9%) stop at 75 or younger; 34 take children under 18; 288 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Alzheimer Disease by Eisai Co., Ltd., or all of them as a file.
02

Study summary

The primary objective of this study is to develop and validate claims-based algorithms to identify intracerebral hemorrhage >1 cm in diameter, ensuring differentiation from amyloid-related imaging abnormality-microhemorrhage and hemosiderin deposit (ARIA-H; microhemorrhage, superficial siderosis) in participants with Alzheimer's disease (AD) using claims data in the United States (US) with linkage to electronic health records (EHRs), and to estimate the positive predictive values (PPVs) of the algorithms. The secondary objective of the study is to validate claims-based algorithms to identify new-onset seizures in participants with AD using US claims data with linkage to EHRs and to estimate the PPVs of the algorithms.

Read the detailed description

As this is a Retrospective Database Study, the Study Start Date for this study references the date at which the first set of data will become available.

03

Conditions studied

  • Alzheimer's Disease

Keywords

  • Alzheimer's Disease
  • Intracerebral Hemorrhage
  • Seizures
  • US Healthcare Claims Data
04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

The study includes participants with at least one Alzheimer's disease diagnosis in claims data from January 2016 to July 2025 (or the latest available data).

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Before or on the outcome event date, have at least 1 ICD-10-CM diagnosis code for AD in medical claims in an inpatient setting; or have at least 2 ICD-10-CM diagnosis codes in medical claims in an outpatient setting, at least 7 days and less than 365 days apart
  • Have at least 365 days of continuous coverage with medical and pharmacy benefits before the outcome event date
  • Have EHR data available for (1) the outcome event date or (2) during the period of up to 30 days before and up to 90 days after the outcome event date
  • Have unstructured EHR information (ie, clinical notes) available for any encounter (1) on the outcome event date or (2) during the period of 30 days before to up to 45 days after the outcome event date

Exclusion criteria

Exclusion Criteria:

  • New-onset seizure outcome only: Have any ICD-10-CM diagnosis code for seizure or epilepsy before the outcome event date
05

Study design

Observational model
Cohort
Time perspective
Retrospective
Enrollment
600 participants (estimated)
Patient registry
No

Groups and cohorts

  • Alzheimer's Disease Participants in US Claims-EHR Data

    Other: No intervention

Interventions

  • OtherNo intervention

    This is a non-interventional study.

06

What researchers measure

Primary outcomes

  1. Positive Predictive Value (PPV) of algorithms to identify intracerebral hemorrhage >1 cm in diameter

    Time frame: Up to 9.5 years

Secondary outcomes

  1. PPV of algorithms to identify new-onset seizure

    Time frame: Up to 9.5 years

07

Study locations

1 site
  • Eisai Site #1
    Nutley, New Jersey 07110, United States
08

References and documents

Individual participant data

Plan to share: Yes — Eisai's data sharing commitment and further information on how to request data can be found on our website http://eisaiclinicaltrials.com/

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2026 (actual). Primary completion is estimated for Dec 2029, 43 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 20, 2026: primary completion Dec 2026 → Dec 2029 and completion Dec 2026 → Dec 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 20, 2026
First posted
Jul 23, 2026
StartActual
May 11, 2026
Primary completionEst.
Dec 31, 2029was Dec 2026
CompletionEst.
Dec 31, 2029was Dec 2026
Last update
Oct 20, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Dec 31, 2026→Dec 31, 2029
Oct 20, 2026
Study completion
Dec 31, 2026→Dec 31, 2029
Oct 20, 2026
Show all 1 update
  1. Oct 20, 2026
    Primary completion Dec 31, 2026→Dec 31, 2029
    Study completion Dec 31, 2026→Dec 31, 2029

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07723950
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Jul 23, 2026
Start date
May 11, 2026
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Oct 20, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion